Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00829296 · ClinicalTrials.gov registry record · Phase 2

Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries

A Phase 2 study, sponsored by University of Chicago.

Completed
Registry status
Phase 2
Development phase
70
Enrollment target

NCT00829296 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 70 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00829296, a Phase 2 study, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 2
Development phase
70 participants
Enrollment target

Study Summary

The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.

Interventions

  • DRUG Metoprolol
  • DRUG nebivolol

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2009-01
Est. Completion 2013-04
Phase Phase 2

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT00829296

The ClinicalTrials.gov registry entry for NCT00829296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Metoprolol is the first listed.

NCT00829296 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00829296 about?

NCT00829296 is a clinical study titled "Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries". The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.

What is the current status of trial NCT00829296?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2009-01. Estimated completion is 2013-04.

What interventions are being tested in trial NCT00829296?

The interventions under investigation include: Metoprolol (DRUG), nebivolol (DRUG).

Who is sponsoring clinical trial NCT00829296?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.